SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome | MicrobiomeTrials← Back to trialsNCT07214818
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2025-11-15Est. Completion: 2026-07-05
Enrollment target: 75 participants Locations- Urology & Nephrology Center, Mansoura University, Al Mansurah, Dakahlia Governorate, Egypt
Other microbiome trials you might be interested in
Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change DiseaseMinimal Change Nephrotic SyndromeMembranous NephropathyFSGSMCDMCD - Minimal Change DiseaseAlport Syndrome
NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicat…
Atlanta, United StatesEst. completion Dec 30, 2029
Minimal Change Disease (MCD)Membranous NephropathyGlomerulosclerosis, Focal Segmental
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an en…
Los Angeles, United StatesEst. completion Dec 31, 2030
Nephrotic SyndromeLipodystrophyMetabolic SyndromeHealthy VolunteerDiabetesMetabolic Associated Steatotic Liver Disease
Background:
Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn mo…
Bethesda, United StatesEst. completion Feb 1, 2030